Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer

BACKGROUND: Evidence from a retrospective analysis of multiple large phase iii trials suggested that primary tumour location (ptl) in RAS wild-type metastatic colorectal cancer (wtRAS mcrc) might have predictive value with respect to response to drug therapies. Recent studies also show a potential p...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Oncol
Asıl Yazarlar: Wong, W.W.L., Zargar, M., Berry, S.R., Ko, Y.J., Riesco-Martínez, M., Chan, K.K.W.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Multimed Inc. 2019
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6821119/
https://ncbi.nlm.nih.gov/pubmed/31708653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4843
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller